June 25, 2012 -- CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, is delighted to announce that it has won the Best Technology category at the 10th annual European Mediscience Awards, which were held in London on June 21st 2012.
The voting panel, consisting of European finance and life science professionals, chose CARMAT for the highly innovative nature of its total artificial heart project, and has rewarded its ability to finance itself and to generate significant future commercial success.
Marcello Conviti, CEO of CARMAT, comments: “We are very pleased that our company has attracted people’s attention across the Channel, particularly as the voting panel consists of recognized life science experts. I would like to thank them, as well as all of our teams and partners whose daily involvement and commitment is enabling our unique project to move forward.”
About the European Mediscience Awards
The European Mediscience Awards have been held since 2002 and celebrate the best in the quoted life science, healthcare and biotech industries. The event has grown to be the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe, attracting over 500 attendees.
More info at: www.mediscience-event.co.uk
About CARMAT: CARMAT, the world’s most advanced total artificial heart project
The only credible response for all cases of end-stage heart failure - a true public health issue: CARMAT’s ultimate aim is to provide a response to a major public health issue associated with cardiovascular disease, the world’s leading cause of death: heart failure. This disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from end-stage heart failure.
The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves - most widely used worldwide - and the technological expertise of EADS, a global aerospace leader.
Imitating the natural heart: Given its size and weight, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit tens of thousands of patients a year – with no risk of rejection and providing them with unparalleled quality of life.
A project leader acknowledged at the European level: with the backing of the European Commission, CARMAT has received the largest grant-in-aid (a total of €33m) made to an SME by OSEO (the French state innovation agency).
Strongly committed, prestigious founders and shareholders: Truffle Capital (the leading European venture capital firm), EADS, the Foundation Alain Carpentier, the Marie Lannelongue Cardiothoracic Centre and thousands of institutional and individual shareholders have placed their trust in CARMAT.
For further information, visit: www.carmatsa.com
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT (“the Company”) in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence registered with the Autorité des Marchés Financiers under number R.11-017 on April 27th 2011 and the Note d’Opération that was approved with visa no. 11-308 on July 11th 2011, changes in economic conditions, the financial markets or the markets in which Carmat operates. In particular, no guarantee can be given concerning the Company’s ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the AFSSAPS, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark.
Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR
CARMAT
Marcello Conviti
CEO
Patrick Coulombier
COO
or
Valérie Leroy, +33 (0)1 39 45 64 50
Marketing and Investor Relations Director
contact@carmatsas.com
or
Alize RP
Press Relations
Caroline Carmagnol, +33 (0)6 64 18 99 59
caroline@alizerp.com
or
NewCap.
Financial communication and investor relations
Dusan Oresansky / Emmanuel Huynh, +33 (0)1 44 71 94 94
carmat@newcap.fr
